Let’s Talk Retina: an Evolve Medical Education Podcast
Evolve Medical Education, LLC
15 episodes
8 months ago
This podcast features subject matter experts from around the globe discussing all things retina, including diagnosis of retinal diseases, advanced imaging, and cutting-edge medical and surgical treatments, with candid conversations about the future of retinal disease therapies.
All content for Let’s Talk Retina: an Evolve Medical Education Podcast is the property of Evolve Medical Education, LLC and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
This podcast features subject matter experts from around the globe discussing all things retina, including diagnosis of retinal diseases, advanced imaging, and cutting-edge medical and surgical treatments, with candid conversations about the future of retinal disease therapies.
Considerations for More Durable Agents in Treatment of Neovascular Age-Related Macular Degeneration: Data Review and Case Studies
Let’s Talk Retina: an Evolve Medical Education Podcast
25 minutes
1 year ago
Considerations for More Durable Agents in Treatment of Neovascular Age-Related Macular Degeneration: Data Review and Case Studies
David Chin Yee, MD, FASRS and Esther Lee Kim, MD, discuss clinical trial data of newer, longer duration retinal disease therapies and share real-world case studies utilizing these new agents for their patients.
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
Click here to view the webinar event, which includes images from the talk.
Check out the central hub of this webinar series.
Want to register with Evolve Medical Education? Click here.
Let’s Talk Retina: an Evolve Medical Education Podcast
This podcast features subject matter experts from around the globe discussing all things retina, including diagnosis of retinal diseases, advanced imaging, and cutting-edge medical and surgical treatments, with candid conversations about the future of retinal disease therapies.
